Agennix Inc.

12 articles about Agennix Inc.

• Agennix AG Reports Financial Results for Second Quarter and First Half of 2012

  7/31/2012

• Stem Cell Innovations to Provide Research and Assay Services to Agennix Inc.

  3/2/2010

• Agennix Inc. Expands Talactoferrin Phase 3 FORTIS-M Registration Trial Globally

  1/21/2010

• GPC Biotech AG Provides Update on Merger with Agennix Inc.

  10/8/2009

• Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

  5/20/2009

• GPC Biotech AG and Agennix Announce Proposed Merger

  2/18/2009

• Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis

  4/22/2008

• Agennix's Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer

  2/26/2008

• Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer Trial

  1/17/2008

• Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin

  6/4/2007

• Agennix Receives FDA Orphan Drug Designation For Talactoferrin Alfa In Renal Cell Carcinoma

  10/12/2006

• Agennix Receives FDA Fast Track Designation For Talactoferrin Alfa In Non-Small Cell Lung Cancer And Diabetic Foot Ulcers

  10/5/2006